MedTrace Logo

Real-world Outcomes of Patients With HER2+ Metastatic Breast Cancer After Treatment With Trastuzumab Deruxtecan

NCT06833268 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 228

Last updated 2025-07-08

No results posted yet for this study

Summary

This study will explore treatment patterns and clinical outcomes using the US-based Flatiron Health database to describe patients with HER2+ mBC who were previously treated with T-DXd to better characterize this population and inform internal decision making in this rapidly changing therapeutic landscape.

Conditions

Interventions

OTHER

No drug

This is an non-interventional, observational study. No drug will be provided or administered as part of this protocol.

Sponsors & Collaborators

Principal Investigators

  • Project Manager · Daiichi Sankyo

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-01-20
Primary Completion
2025-06-16
Completion
2025-06-16

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06833268 on ClinicalTrials.gov